December 2024: Who bagged the biggest private biotech investments?
This issue of our newsletter is supported by Inpart.
As we bid farewell to 2024, the final month of the year brought with it some big fundraising rounds. For example, in the biggest investment of December, Nuvig Therapeutics raised $161 million in a series B round, as it aims to deliver novel methods for reducing autoimmune dysregulation without immunosuppression.
Meanwhile, Ottimo Pharma wasn’t far behind after bagging $140 million from a series A round, helping its ambition of developing a cancer drug that blocks PD-1 and VEGF, and Angitia Biopharmaceuticals managed to raise $120 in a series C round to support its pipeline of treatments for serious musculoskeletal diseases.
And, as we also looked back at 2024 as a whole, we found that, although October was the month with the highest amount of fundraising rounds, it was actually April that brought in the most amount of money.
To find out more, read the full article: “The biggest private biotech investments in December 2024”
A MESSAGE FROM OUR SPONSOR INPART
Partnering 2030: Biopharma report
Download Inpart’s latest report to hear from biotechs and out-licensors, following this year’s Partnering 2030 survey. The report includes real-world partnering experiences, challenges, and insights into working with top pharmaceutical firms.
领英推荐
Want to advertise with us? Become our next sponsor.
?? More noteworthy articles from this week:
Partnerships in the biopharma industry have been a long-standing measure of research and development (R&D). Last month saw a number of alliances forming in a range of therapeutic spaces but there has been one serial collaborator that stands out – GSK. The British pharma giant seems to have embarked on a dealmaking journey across the globe to strengthen its presence in various fields.
Starting a biotech is a daunting task with a lot of parameters. And if you’re only starting, the chances are you don’t have all the resources and knowledge it takes to be successful or as efficient as possible yet. This is where biotech incubators can be useful, decisive even. But that doesn’t mean they’re all right for you. So, let’s take a look at the things to consider when deciding on an incubator to make sure you “choose wisely.”
The biopharma industry’s pursuit of streamlining complex development and manufacturing workflows is driven by process intensification and integration of automation, continuous processing, and single-use system solutions. This strategy is especially relevant in the current landscape, where recent global health crises are directing the adoption of more versatile and economical manufacturing solutions while adhering to stringent regulatory requirements.
??Enjoying these articles??Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.